Skip to main content

29-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: The SPARTAN OS data

Boris Hadaschik discusses the final overall survival analysis of the phase 3 placebo-controlled SPARTAN trial of apalutamide for nonmetastatic castration-resistant prostate cancer (6:00).

Read transcript

Have your say on Medicine Matters

Visit the conference hub

Image Credits